ArticleJAMA2019
Trends in Medicaid Prices, Market Share, and Spending on Long-Acting Insulins, 2006-2018.
Article in JAMA, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Recommendations for Interchangeability in a Growing Biosimilar Market in Latin America.Advances in therapy · 2024Review
- Impact of list price changes on out-of-pocket costs and adherence in four high-rebate specialty drugs.PloS one · 2023Article
- Prescriber Perspectives on Biosimilar Adoption and Potential Role of Clinical Pharmacology: A Workshop Summary.Clinical pharmacology and therapeutics · 2023Review
- Consequences of forgoing prescription drug subsidies among low-income Medicare beneficiaries with diabetes.Health services research · 2022Article
- Real-World Impact of Switching From Insulin Glargine (LantusFrontiers in public health · 2022Article
- Estimation of the Share of Net Expenditures on Insulin Captured by US Manufacturers, Wholesalers, Pharmacy Benefit Managers, Pharmacies, and Health Plans From 2014 to 2018.JAMA health forum · 2021Article
- Trends in Insulin Types and Devices Used by Adults With Type 2 Diabetes in the United States, 2016 to 2020.JAMA network open · 2021Article
- Barriers to Uptake of Insulin Technologies and Novel Solutions.Medical devices (Auckland, N.Z.) · 2021Review
- A Decade of Disparities in Diabetes Technology Use and HbADiabetes care · 2021Article
- Differences Between Managed Care and Fee-for-Service Medicaid in the Use of Generics for High-Rebate Drugs: The Cases of Insulin Glargine and Glatiramer.Journal of managed care & specialty pharmacy · 2020Article
- Origins of the Crisis in Insulin Affordability and Practical Advice for Clinicians on Using Human Insulin.Current diabetes reports · 2020Review
- Trends in List Prices, Net Prices, and Discounts for Originator Biologics Facing Biosimilar Competition.JAMA network open · 2019Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.